{"product_id":"ampe-vrio-analysis","title":"Ampio Pharmaceuticals, Inc. (AMPE): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eDiscover the core of what makes Ampio Pharmaceuticals, Inc. (AMPE) a true market contender! Our VRIO analysis cuts straight to the heart of its competitive edge, examining the Value, Rarity, Inimitability, and Organization of its key resources. \u0026amp;O4\u0026amp; reveals the critical insights - will this foundation secure sustained success or expose a vulnerability? Dive in below to uncover the full strategic breakdown and what it means for the future of Ampio Pharmaceuticals, Inc. (AMPE).\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAmpio Pharmaceuticals, Inc. (AMPE) - VRIO Analysis: Intellectual Property Portfolio (Ampion\/OA-201 Patents)\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at the residual value of Ampio Pharmaceuticals, Inc. (AMPE) assets after the company dissolved. The core question for this IP portfolio is whether the patents on Ampion\/OA-201 still hold value given the company ceased operations as of \u003cstrong\u003eAugust 16, 2024\u003c\/strong\u003e. Here’s the quick math on what remains.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eIntellectual Property Portfolio (Ampion\/OA-201 Patents)\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The patents hold coverage in major jurisdictions, which was intended to extend exclusivity for the OA-201 program, the primary value driver for any residual licensing or sale. As of earlier filings, the portfolio included up to \u003cstrong\u003e127 issued patents and 80 pending applications\u003c\/strong\u003e across seven primary families, with some expirations extending to \u003cstrong\u003e2035\u003c\/strong\u003e. The value now hinges entirely on the ability of a third party to acquire and enforce these rights, especially since the IND submission for OA-201 was deemed unsupported by late preclinical data in early 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many biotechs have intellectual property, but specific composition or method patents for a novel biologic like Ampion, which is a low molecular weight fraction of human serum albumin, are less common. The portfolio covered global jurisdictions including the U.S., Europe, and China.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult. The patents are legally protected barriers; imitation would require designing around complex claims or waiting for expiration. However, the lack of an active development organization significantly reduces the practical difficulty of imitation for a competitor who might acquire the assets or develop a non-infringing alternative without the overhead of defending the IP.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Low. This is the critical constraint. Ampio Pharmaceuticals dissolved as of \u003cstrong\u003eAugust 16, 2024\u003c\/strong\u003e. The organization is no longer focused on active commercialization, defense, or further development of the OA-201 program, which management noted in February 2025 did not support an IND submission. Any remaining value is managed through the dissolution process, subject to court approval for final distributions.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The patents themselves provide a temporary legal barrier, but the company's dissolved status limits its ability to exploit this advantage or invest in defending it. The market reflects this low organizational capacity, with the stock trading around \u003cstrong\u003e$0.0052\u003c\/strong\u003e on November 25, 2025.\u003c\/p\u003e\n\n\u003cp\u003eHere is a summary of the VRIO assessment for this key asset:\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n    \u003ctd\u003eAssessment\u003c\/td\u003e\n    \u003ctd\u003eImplication\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003ePotential residual licensing\/sale value exists in the patent estate.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eSpecific composition\/method patents for Ampion are unique.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003eDifficult\u003c\/td\u003e\n    \u003ctd\u003eLegal protection exists against direct copying.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eNo\u003c\/td\u003e\n    \u003ctd\u003eCompany is dissolved as of \u003cstrong\u003eAugust 16, 2024\u003c\/strong\u003e; no structure to exploit IP.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n    \u003ctd\u003eTemporary\u003c\/td\u003e\n    \u003ctd\u003eLegal barrier exists, but organizational failure prevents sustained advantage capture.\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the specific cost and timeline for a third party to acquire the rights from the dissolved entity and the Delaware Chancery Court proceedings. If onboarding takes 14+ days, churn risk rises - though here, the risk is that the IP rights transfer process stalls indefinitely.\u003c\/p\u003e\n\u003cp\u003eFinance: draft a memo detailing the known patent expiration dates (up to \u003cstrong\u003e2035\u003c\/strong\u003e) and the status of the dissolution proceedings by next Tuesday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAmpio Pharmaceuticals, Inc. (AMPE) - VRIO Analysis: Preclinical Asset: AR-300 Development Program\n\u003c\/h2\u003e\n\u003cp\u003eThe analysis below assesses the AR-300 development program, a novel, proprietary, small molecule formulation, within the context of Ampio Pharmaceuticals, Inc.'s operational status.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Represents a potential derivative asset leveraging key attributes of Ampion, offering a secondary, albeit early-stage, value proposition for a potential acquirer. This potential was significantly diminished by the February 14, 2024, announcement that efficacy results from nonclinical studies did not support an Investigational New Drug (“IND”) submission for the related OA-201 program, leading to the termination of that program.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many companies have preclinical assets, but one directly derived from a late-stage candidate has unique lineage.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. The underlying science might be imitable, but the specific data package and derivation from Ampion are unique to Ampio.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Low. As a dissolved entity, there is no active R\u0026amp;D organization to advance this asset; its value is passive. The Certificate of Dissolution was effective August 16, 2024.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Value is contingent on a third party acquiring and advancing the asset; the current organization cannot sustain it, as operations ceased upon dissolution.\u003c\/p\u003e\n\n\u003cp\u003eThe following table summarizes key data points relevant to the asset's context and the company's final status:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eReference Date\/Status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsset Development Stage\u003c\/td\u003e\n\u003ctd\u003ePreclinical\u003c\/td\u003e\n\u003ctd\u003eAs of March 27, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical Data Expectation (Pain\/Chondroprotection)\u003c\/td\u003e\n\u003ctd\u003eFirst half of 2023\u003c\/td\u003e\n\u003ctd\u003eJanuary 17, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRelated Program (OA-201) Termination\u003c\/td\u003e\n\u003ctd\u003ePain reduction benefit not observed in larger trials\u003c\/td\u003e\n\u003ctd\u003eFebruary 14, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany Status\u003c\/td\u003e\n\u003ctd\u003eDissolved\u003c\/td\u003e\n\u003ctd\u003eEffective August 16, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear ended 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany Classification\u003c\/td\u003e\n\u003ctd\u003ePre-revenue stage\u003c\/td\u003e\n\u003ctd\u003ePrior to dissolution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe asset's potential was tied to specific preclinical findings, which are summarized below:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDemonstrated anti-inflammatory properties \u003cem\u003ein vitro\u003c\/em\u003e.\u003c\/li\u003e\n\u003cli\u003eDemonstrated protection of cartilage in preclinical rat meniscal tear studies.\u003c\/li\u003e\n\u003cli\u003ePrevious smaller studies showed efficacy versus saline control to reduce pain and preserve cartilage in nonclinical models of osteoarthritis of the knee.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAmpio Pharmaceuticals, Inc. (AMPE) - VRIO Analysis: Cash Position and Liquidation Process\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eThe remaining cash, after settling legal obligations approved by the Delaware Chancery Court, is the only direct distributable asset to stockholders.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eLow. All companies in dissolution have a cash position, but the amount remaining post-litigation is unique.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eNot Applicable. This is a financial state, not a capability to be imitated.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eHigh. The CEO and legal teams are actively organized around this process, as per the March 2024 determination to pursue delisting to fund an orderly wind down of operations. \u003cstrong\u003eCEO\u003c\/strong\u003e and legal teams are actively organized around this process.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eSustained (for the process). The legal structure governing the distribution is a necessary, sustained process until completion.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003eDate\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.08 Million USD\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of December 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Short Term Investments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.09 Million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBalance Sheet Period Ending (Latest Reported Period)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Ratio (TTM\/Annual\/Quarterly)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.72\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Reporting Period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutstanding Shares of Common Stock\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e832,021\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of November 10, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Average Recovery Per Share (Pre-Fees)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.02\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eClass Action Settlement Estimate (January 2025 Notice)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Average Recovery Per Share (Post-Fees)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.015\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eClass Action Settlement Estimate (January 2025 Notice)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eCash and cash equivalents were \u003cstrong\u003e$12.7 million\u003c\/strong\u003e as of December 31, 2022.\u003c\/li\u003e\n\u003cli\u003eThe company announced steps to voluntarily delist and deregister in March 2024 to ensure sufficient cash to fund an orderly wind down.\u003c\/li\u003e\n\u003cli\u003eThe Class Period for the class action lawsuit was December 29, 2020 through August 3, 2022.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cbr\u003e\u003ch2\u003eAmpio Pharmaceuticals, Inc. (AMPE) - VRIO Analysis: Clinical Data Package for Osteoarthritis of the Knee (OAK)\n\u003c\/h2\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eContains data from \u003cstrong\u003eseven Phase 2\/3 trials\u003c\/strong\u003e involving over \u003cstrong\u003e1,500 treated patients\u003c\/strong\u003e, which is a significant historical data asset for future meta-analyses or secondary indications. The data package includes results from pivotal trials such as AP-013, which involved an \u003cstrong\u003en=618\u003c\/strong\u003e modified Intent-to-Treat population.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial Metric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Phase 2\/3 Trials (as per outline)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Treated Patients (as per outline)\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e1,500\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAP-013 mITT Population Size\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e618\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAP-013 Pain Reduction P-value vs Saline\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.042\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAP-013 Function Improvement P-value vs Saline\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.027\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerate. Large, multi-trial datasets are valuable, though this one is complicated by past \u003cstrong\u003eFDA feedback regarding saline response\u003c\/strong\u003e. The FDA accepted AP-003-A as the first of \u003cstrong\u003etwo\u003c\/strong\u003e required Phase 3 pivotal studies.\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eEasy. The data itself is historical and can be reviewed by any competitor or researcher.\u003c\/p\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eLow. The organization is not structured to actively market or defend this data package now. Financial data indicates a \u003cstrong\u003e$1.6 million\u003c\/strong\u003e impairment loss recorded in the third quarter of \u003cstrong\u003e2022\u003c\/strong\u003e related to assets. As of December 31, 2022, Cash \u0026amp; Cash Equivalents were \u003cstrong\u003e$4.12 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eNone. Historical data is a sunk cost and not a source of sustained advantage in a dissolved state.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eSafety Database Scope:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eBelieved to be the largest safety database for any drug treating severe OAK across \u003cstrong\u003efour\u003c\/strong\u003e earlier clinical trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eOne trial included over \u003cstrong\u003e100\u003c\/strong\u003e patients receiving repeated injections over \u003cstrong\u003e52\u003c\/strong\u003e weeks.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eFinancial Position (as of Dec 31, 2022):\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eTotal Debt: \u003cstrong\u003e$451,000\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eNet Cash Position: \u003cstrong\u003e$3.67 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAmpio Pharmaceuticals, Inc. (AMPE) - VRIO Analysis: Inhaled Therapeutic Program: AMP5A (COVID-19)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Represents a distinct, albeit paused, immunomodulatory application with positive Phase I safety data and a completed Phase II trial initiation for respiratory complications.\u003c\/p\u003e\n\u003cp\u003eThe Phase I AP-014 trial demonstrated significant efficacy signals:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe primary endpoint of safety and tolerability was met.\u003c\/li\u003e\n\u003cli\u003eAmpion reduced all-cause mortality by \u003cstrong\u003e78%\u003c\/strong\u003e over the Standard of Care (SOC).\u003c\/li\u003e\n\u003cli\u003eMortality rates were \u003cstrong\u003e5%\u003c\/strong\u003e in the Ampion group versus \u003cstrong\u003e24%\u003c\/strong\u003e in the SOC group.\u003c\/li\u003e\n\u003cli\u003eSubjects treated with AMP5A showed shorter hospital stays, averaging \u003cstrong\u003e8 days\u003c\/strong\u003e versus \u003cstrong\u003e12 days\u003c\/strong\u003e for the control group.\u003c\/li\u003e\n\u003cli\u003eThe Phase II AP-019 trial completed interim enrollment with \u003cstrong\u003e129\u003c\/strong\u003e patients in the first quarter of 2022.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAMP5A (Inhaled Ampion) Group\u003c\/th\u003e\n\u003cth\u003eStandard of Care (SOC) Group\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase I Subjects Enrolled\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e19\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e21\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAll-Cause Mortality\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e24%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAverage Hospital Stay (Days)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e12\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eICU Admission Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e21%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e33%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Having a separate, tested formulation and indication pathway is not common for a company with a market capitalization of \u003cstrong\u003e$1.85M\u003c\/strong\u003e (as of March 15, 2024).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult. The specific formulation and trial data are proprietary, though the underlying mechanism might be known.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe drug is described as a novel, low-molecular-weight fraction of human serum albumin.\u003c\/li\u003e\n\u003cli\u003eIntellectual property protection extends through \u003cstrong\u003e2037\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Low. The focus is dissolution, not advancing this specific program, making its exploitation passive.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAs of March 2022, the company projected its cash position of \u003cstrong\u003e$34 Million\u003c\/strong\u003e in cash and cash equivalents would fund current operations into the second half of \u003cstrong\u003e2023\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal Assets were reported as \u003cstrong\u003e$5,736 thousand\u003c\/strong\u003e (USD) as of December 31, 2023.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Any value is tied to a potential buyer seeing utility in the data\/formulation, which is a one-time event.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAmpio Pharmaceuticals, Inc. (AMPE) - VRIO Analysis: Institutional Knowledge of Regulatory Pathways\n\u003c\/h2\u003e\n\u003cp\u003e\nThe analysis focuses on the institutional knowledge related to navigating the FDA for the Biologics License Application (BLA) for Ampion for severe Osteoarthritis of the Knee (OAK).\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eRegulatory\/Financial Metric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eContext\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmpion IND Applications Withdrawn\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJanuary 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA Request for Additional Trial (Ampion)\u003c\/td\u003e\n\u003ctd\u003eSetback for BLA submission\u003c\/td\u003e\n\u003ctd\u003eAugust 2018\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFYE 2023 Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$-8.63M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2023-12-31\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFYE 2023 Operating Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9.57M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2023-12-31\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany Employee Count\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11-50\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCurrent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\n\u003cp\u003e\n\u003cstrong\u003eValue:\u003c\/strong\u003e The accumulated experience navigating the FDA for a novel biologic (BLA) for OAK, even with setbacks, is valuable tacit knowledge for any entity acquiring the IP.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Deep, specific experience with a particular drug class and regulatory hurdle is rare.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult. Tacit knowledge is hard to transfer; it resides in the few remaining personnel.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eOrganization:\u003c\/strong\u003e Low. This knowledge is not codified or actively used for new filings; it's latent.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It only provides an advantage if the acquiring entity retains key personnel or uses the knowledge immediately.\n\u003c\/p\u003e\n\n\u003cp\u003e\nKey Regulatory Milestones Related to Institutional Knowledge:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e \nThe initial acceptance of study AP-003-A as a pivotal trial for the BLA, following a pre-BLA meeting in October 2013.\n\u003c\/li\u003e\n\u003cli\u003e \nThe subsequent FDA request in July 2018 for an additional randomized trial with a concurrent control group for Ampion, despite the company believing its data was sufficient.\n\u003c\/li\u003e\n\u003cli\u003e \nThe formal discontinuation of Ampion development and withdrawal of 3 Investigational New Drug (IND) applications, including the one for Osteoarthritis, in January 2023.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAmpio Pharmaceuticals, Inc. (AMPE) - VRIO Analysis: Small, Specialized Employee Base\n\u003c\/h2\u003e\n\u003cp\u003eThe operational structure of Ampio Pharmaceuticals, Inc. post-termination of its primary development program and initiation of a wind-down process centers on a significantly reduced and specialized workforce.\u003c\/p\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eA lean team, noted as having been reduced to \u003cstrong\u003efive employees\u003c\/strong\u003e by early 2023, focused solely on winding down legal and financial obligations minimizes ongoing burn rate during the dissolution phase. This structure directly supports the stated board determination to 'ensure sufficient cash to adequately fund an orderly wind down of the Company's operations and to maximize the Company's cash position'.\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eThe transition to a minimal staff is \u003cstrong\u003eLow\u003c\/strong\u003e in rarity for a development-stage biotech that has ceased active product development and is pursuing voluntary delisting and SEC deregistration. Historically, the employee base was in the 11-50 range [cite: 1 from previous search].\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eReducing headcount to a core legal\/finance team for dissolution is a standard, \u003cstrong\u003eEasy\u003c\/strong\u003e to replicate action within the biopharmaceutical industry following strategic failure or asset divestiture.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eThe current structure is described as \u003cstrong\u003eHigh\u003c\/strong\u003e in organization, being highly focused around the single, defined goal of dissolution and asset distribution, which is evidenced by the formal steps taken for delisting and suspension of reporting obligations [cite: 3, 6 from previous search].\u003c\/p\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eThe lean structure provides a \u003cstrong\u003eTemporary\u003c\/strong\u003e advantage, as this cost-saving structure is only beneficial until the dissolution and asset distribution process is complete.\u003c\/p\u003e\n\u003cp\u003eThe financial context supporting the need for this lean structure, based on the Form 10-Q for the quarter ended September 30, 2023, which reflects adjustments for a 20-to-1 reverse stock split effective September 12, 2023, is detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric (As of September 30, 2023)\u003c\/th\u003e\n\u003cth\u003eAmount (USD)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Liabilities and Stockholders' Equity (Total Assets)\u003c\/td\u003e\n\u003ctd\u003e$\u003cstrong\u003e7,646,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Stockholders' Equity\u003c\/td\u003e\n\u003ctd\u003e$\u003cstrong\u003e5,375,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommon Stock Shares Issued and Outstanding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e804,604\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFurther details on the organizational status include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company was classified as a \u003cstrong\u003eNon-Accelerated Filer\u003c\/strong\u003e and a \u003cstrong\u003eSmaller reporting company\u003c\/strong\u003e as of September 30, 2023 [cite: 5 from previous search].\u003c\/li\u003e\n\u003cli\u003eThe board determined to take steps designed to 'maximize the Company's cash position' [cite: 3, 6 from previous search].\u003c\/li\u003e\n\u003cli\u003eThe company announced its intention to file a Form 15 with the SEC to suspend its reporting obligations under the Exchange Act following delisting [cite: 3, 6 from previous search].\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAmpio Pharmaceuticals, Inc. (AMPE) - VRIO Analysis: Former Commercial Partnering Experience\n\u003c\/h2\u003e\n\u003cp\u003eThe history of engaging with large commercial partners to fund late-stage development provides a reference point for valuing the remaining assets to potential buyers.\u003c\/p\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eThe history of engaging with large commercial partners to fund late-stage development provides a reference point for valuing the remaining assets to potential buyers.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company's operating plan, prior to a potential partnership, was supported by a registered direct offering that provided approximately \u003cstrong\u003e$21 million\u003c\/strong\u003e in net proceeds.\u003c\/li\u003e\n\u003cli\u003eThis financing, combined with expected year-end 2021 cash, translated to a total of approximately \u003cstrong\u003e$34 million\u003c\/strong\u003e, intended to cover more than a year and a half of cash at the burn rate at that time.\u003c\/li\u003e\n\u003cli\u003eThe company was exploring interest from large commercial partners for Ampion, with a strategy to obtain comprehensive intellectual property protection extending through 2035.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eModerate. Experience in high-stakes partnership negotiations is a specific skill set.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAsset\/Program\u003c\/th\u003e\n\u003cth\u003ePartnering Focus Period\u003c\/th\u003e\n\u003cth\u003eKey Financial Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmpion\u003c\/td\u003e\n\u003ctd\u003eExploration noted around 2017\u003c\/td\u003e\n\u003ctd\u003eSeeking significant investment for worldwide commercial launch.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAR-300\u003c\/td\u003e\n\u003ctd\u003eExploration mentioned post-May 2022\u003c\/td\u003e\n\u003ctd\u003eDevelopment contingent on positive preclinical data and securing a corporate partnership.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eEasy. The record of past negotiations is available internally, but the skill is hard to replicate without the people.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company's intellectual property portfolio for Ampion included \u003cstrong\u003e125\u003c\/strong\u003e issued patents and \u003cstrong\u003e85\u003c\/strong\u003e pending applications across seven primary patent families as of March 2017.\u003c\/li\u003e\n\u003cli\u003eThe company engaged an exclusive placement agent in June 2019 to assist in selling common shares to investors.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eLow. The organization is not currently in a partnering mode; it is in a liquidation mode.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eValue\/Status\u003c\/th\u003e\n\u003cth\u003eDate\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eS$4.38 Million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of December 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares Outstanding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e15,102,877\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of March 22, 2023 (pre-reverse stock split)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiquidation\/Dissolution Risk\u003c\/td\u003e\n\u003ctd\u003eExplicitly mentioned as a potential path\u003c\/td\u003e\n\u003ctd\u003eDue to limited cash resources and significant liabilities from legal proceedings (as of 2023 10-K).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eNone. Past negotiation history does not create a current advantage in a dissolution scenario.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAmpio Pharmaceuticals, Inc. (AMPE) - VRIO Analysis: Proprietary Drug Development Platform (NMEs\/Pipeline Selection)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The company's stated dedication to developing innovative proprietary drugs chosen from an extensive portfolio suggests an underlying, albeit unproven, platform for identifying New Molecular Entities (NMEs). The platform targeted therapeutic areas including metabolic disease, eye disease, kidney disease, inflammation, sexual dysfunction, and CNS disease. NCE-001, targeting PP2A as a PP2A stimulant, was listed for Alzheimer Disease at the Preclinical phase.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Having a defined, if small, pipeline beyond the lead candidate (like NCE-001 for Alzheimer's) shows breadth. The pipeline included NCE-001 and AR-300, both at the Preclinical phase.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult. The specific selection criteria and internal processes for choosing NMEs are proprietary.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Low. The platform is dormant as the company is dissolved; no new candidates are being generated or advanced. The Certificate of Dissolution was filed as of August 16, 2024.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The platform's value is entirely dependent on an external entity acquiring the rights and reactivating the R\u0026amp;D function.\u003c\/p\u003e\n\n\u003cp\u003eThe following table summarizes the known pipeline assets associated with the platform:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eNME\/Asset\u003c\/th\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003cth\u003eMechanism\u003c\/th\u003e\n\u003cth\u003eActive Indication\u003c\/th\u003e\n\u003cth\u003eHighest Phase\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNCE-001\u003c\/td\u003e\n\u003ctd\u003ePP2A\u003c\/td\u003e\n\u003ctd\u003ePP2A stimulants\u003c\/td\u003e\n\u003ctd\u003eAlzheimer Disease [+1]\u003c\/td\u003e\n\u003ctd\u003ePreclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAR-300\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003ePain\u003c\/td\u003e\n\u003ctd\u003ePreclinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFinance: draft the final cash distribution forecast, subject to court approval, by next Wednesday.\u003c\/p\u003e\n\n\u003cp\u003eRelevant operational and financial statistics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEmployees: \u003cstrong\u003e21\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eEnd Cash (as of 2023-12-31): \u003cstrong\u003e$4.09M\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eHistorical Free Cash Flow: \u003cstrong\u003e-$8.56M\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eMarket Capitalization: \u003cstrong\u003e78.45K\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e52-Week Stock Price Range (prior to Dec 03, 2025): \u003cstrong\u003e$0.0001\u003c\/strong\u003e to \u003cstrong\u003e$0.1643\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eStock Price (as of Dec 03, 2025): \u003cstrong\u003e0.0052\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516111052949,"sku":"ampe-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/ampe-vrio-analysis.png?v=1740146195","url":"https:\/\/dcf-model.com\/fr\/products\/ampe-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}